Physician
Wayne Memorial Hospital
Wayne Memorial Hospital was paid $9.17M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 21% of everything it billed.
33Billing provider infoWAYNE MEMORIAL HOSPITAL
HONESDALE, PA 18431
HONESDALE, PA 18431
33aNPI1124026182assigned 07/13/2005
33bProvider typeNephrology Physician
28Total paid$9.17M
24GClaims263,892
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Nephrology Physician providers in Pennsylvania
Rank by total paid#1 of 149
Median peer was paid$5K
This provider vs. median2,029×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,333 | $59K | |
| 2019 | 1,236 | $14K | |
| 2020 | 32,991 | $897K | |
| 2021 | 123,996 | $3.66M | |
| 2022 | 31,318 | $1.43M | |
| 2023 | 42,942 | $1.88M | |
| 2024incomplete | 30,076 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 21% | 4,479 | 4,392 | $1.94M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 9,414 | 8,457 | $1.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 11,096 | 9,451 | $1.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 11,191 | 9,197 | $728K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.2% | 6,395 | 5,922 | $479K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 1,559 | 1,523 | $286K |
| 80053 | Comprehensive metabolic panel | 2.1% | 18,661 | 17,330 | $194K |
| X0621 | 1.9% | 624 | 342 | $172K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.4% | 2,767 | 2,693 | $131K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 4,692 | 4,586 | $97K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 18,977 | 17,502 | $96K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 2,564 | 2,550 | $95K |
232 more codes
| 300 | Patient transfer system <300 | 1.0% | 1,114 | $94K |
| 80061 | Lipid panel | <1% | 7,193 | $91K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,854 | $91K |
| G0378 | Hospital observation service, per hour | <1% | 184 | $87K |
| 87486 | <1% | 2,247 | $85K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,397 | $84K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,940 | $74K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,608 | $65K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 965 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,948 | $63K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,014 | $55K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,238 | $54K |
| 80050 | General health panel | <1% | 1,279 | $54K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,645 | $52K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 633 | $49K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,618 | $45K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 324 | $35K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 472 | $35K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 699 | $33K |
| 87070 | <1% | 4,171 | $32K | |
| 86617 | <1% | 973 | $30K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,233 | $29K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,092 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,701 | $28K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 159 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,919 | $27K |
| 20610 | <1% | 1,015 | $26K | |
| 86618 | <1% | 1,011 | $25K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 844 | $25K |
| 86803 | <1% | 1,327 | $24K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,038 | $24K |
| 86780 | <1% | 1,588 | $24K | |
| 84484 | <1% | 2,747 | $22K | |
| 84439 | <1% | 2,975 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,827 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,939 | $20K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 451 | $19K |
| 87081 | <1% | 2,664 | $19K | |
| 93307 | <1% | 213 | $18K | |
| 87476 | <1% | 489 | $18K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 362 | $18K |
| 94729 | <1% | 1,549 | $18K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 667 | $18K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,413 | $18K |
| 81001 | <1% | 6,610 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,777 | $17K |
| 82607 | <1% | 1,327 | $16K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 201 | $16K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 548 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 881 | $15K |
| 87340 | <1% | 1,066 | $15K | |
| 94727 | <1% | 1,461 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,108 | $14K |
| 85730 | <1% | 2,345 | $13K | |
| 83690 | <1% | 3,012 | $13K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,009 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 182 | $12K |
| 84702 | <1% | 782 | $12K | |
| 87150 | <1% | 262 | $12K | |
| 83735 | <1% | 1,887 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,150 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 252 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 506 | $11K |
| 80299 | <1% | 444 | $11K | |
| 85610 | <1% | 3,378 | $10K | |
| 87522 | Neg quan hep c or qual rna | <1% | 265 | $10K |
| 87186 | <1% | 1,266 | $10K | |
| X0592 | <1% | 257 | $10K | |
| 83605 | <1% | 1,265 | $10K | |
| 76536 | <1% | 195 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 472 | $9K |
| 84703 | <1% | 923 | $9K | |
| 93000 | <1% | 631 | $9K | |
| 84481 | <1% | 414 | $9K | |
| 73610 | <1% | 482 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,127 | $8K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 111 | $8K |
| 84153 | <1% | 337 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 360 | $8K |
| 73562 | <1% | 532 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 221 | $7K |
| 84146 | <1% | 130 | $7K | |
| 86038 | <1% | 499 | $7K | |
| 87077 | <1% | 880 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 114 | $7K |
| 93971 | <1% | 113 | $7K | |
| 82728 | <1% | 621 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 173 | $7K |
| 80320 | <1% | 571 | $7K | |
| 84466 | <1% | 396 | $7K | |
| 85027 | <1% | 988 | $6K | |
| 84403 | <1% | 239 | $6K | |
| 87040 | <1% | 572 | $6K | |
| 82746 | <1% | 544 | $6K | |
| 94060 | <1% | 957 | $6K | |
| 82570 | <1% | 934 | $6K | |
| 80074 | <1% | 121 | $6K | |
| 83880 | <1% | 235 | $6K | |
| 71250 | <1% | 112 | $6K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 55 | $6K |
| 86665 | <1% | 198 | $5K | |
| 82043 | <1% | 762 | $5K | |
| 73030 | <1% | 376 | $5K | |
| 81003 | <1% | 1,954 | $5K | |
| 86762 | <1% | 257 | $5K | |
| 73630 | <1% | 480 | $5K | |
| 84436 | <1% | 580 | $5K | |
| 94618 | <1% | 487 | $5K | |
| 72110 | <1% | 243 | $5K | |
| 85378 | <1% | 556 | $5K | |
| 86850 | <1% | 619 | $5K | |
| 87088 | <1% | 673 | $5K | |
| 76642 | <1% | 114 | $4K | |
| 82951 | <1% | 338 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 30 | $4K |
| 73110 | <1% | 379 | $4K | |
| 84145 | <1% | 231 | $4K | |
| 73130 | <1% | 353 | $4K | |
| 86003 | <1% | 22 | $4K | |
| 83001 | <1% | 201 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 152 | $4K |
| 85651 | <1% | 1,260 | $3K | |
| 84402 | <1% | 131 | $3K | |
| 86235 | <1% | 109 | $3K | |
| 73502 | <1% | 201 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 80 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 227 | $3K |
| 82670 | <1% | 145 | $3K | |
| 97164 | <1% | 103 | $3K | |
| 83550 | <1% | 633 | $3K | |
| 86431 | <1% | 343 | $3K | |
| 84480 | <1% | 354 | $3K | |
| 93017 | <1% | 75 | $3K | |
| 87581 | <1% | 364 | $3K | |
| 86140 | <1% | 918 | $3K | |
| 74018 | <1% | 192 | $2K | |
| 86664 | <1% | 113 | $2K | |
| 86901 | <1% | 632 | $2K | |
| 86900 | <1% | 632 | $2K | |
| 82150 | <1% | 499 | $2K | |
| 80349 | <1% | 188 | $2K | |
| 83525 | <1% | 205 | $2K | |
| 88142 | <1% | 130 | $2K | |
| 80076 | <1% | 242 | $2K | |
| 83002 | <1% | 120 | $2K | |
| 86800 | <1% | 112 | $2K | |
| 82140 | <1% | 422 | $2K | |
| 82550 | <1% | 330 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 215 | $2K |
| 82784 | <1% | 121 | $2K | |
| 84550 | <1% | 306 | $2K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 16 | $2K |
| 83970 | <1% | 44 | $2K | |
| 90715 | <1% | 116 | $2K | |
| 88307 | <1% | 46 | $2K | |
| 86769 | <1% | 109 | $1K | |
| 93016 | <1% | 69 | $1K | |
| 72100 | <1% | 72 | $1K | |
| 97597 | <1% | 90 | $1K | |
| 83540 | <1% | 167 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $1K |
| 70486 | <1% | 15 | $1K | |
| 82248 | <1% | 187 | $1K | |
| 83615 | <1% | 187 | $1K | |
| 86757 | <1% | 48 | $1K | |
| 86376 | <1% | 147 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 563 | $1K |
| 86706 | <1% | 85 | $1K | |
| 93970 | <1% | 13 | $1K | |
| 84156 | <1% | 288 | $1K | |
| 73080 | <1% | 93 | $968.55 | |
| 93018 | <1% | 69 | $940.59 | |
| 86255 | <1% | 58 | $923.02 | |
| 72050 | <1% | 35 | $859.54 | |
| 83655 | <1% | 79 | $800.50 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $718.05 |
| 80178 | <1% | 99 | $700.37 | |
| 80164 | <1% | 37 | $623.96 | |
| 81025 | <1% | 224 | $606.80 | |
| 77080 | <1% | 12 | $598.94 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $554.15 |
| 84144 | <1% | 31 | $546.55 | |
| 82977 | <1% | 59 | $510.67 | |
| 80069 | <1% | 61 | $465.00 | |
| 85007 | <1% | 123 | $449.58 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 12 | $396.00 |
| 72070 | <1% | 25 | $393.80 | |
| 82565 | <1% | 68 | $379.97 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 440 | $375.62 |
| 82947 | <1% | 97 | $373.73 | |
| 73090 | <1% | 34 | $357.82 | |
| 73140 | <1% | 42 | $351.10 | |
| 84100 | <1% | 56 | $321.84 | |
| 86677 | <1% | 52 | $301.75 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,344 | $285.61 |
| 82627 | <1% | 13 | $282.45 | |
| 82465 | <1% | 42 | $264.12 | |
| 82962 | <1% | 174 | $263.84 | |
| 12001 | <1% | 12 | $257.30 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31 | $252.00 |
| 84155 | <1% | 54 | $246.26 | |
| 93248 | <1% | 13 | $239.76 | |
| 94010 | <1% | 60 | $235.10 | |
| 82785 | <1% | 13 | $220.40 | |
| 82103 | <1% | 12 | $193.80 | |
| 86704 | <1% | 13 | $188.25 | |
| 96376 | <1% | 42 | $126.22 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 197 | $124.12 |
| 88141 | <1% | 16 | $102.90 | |
| 87147 | <1% | 26 | $74.85 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 474 | $68.84 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 494 | $57.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 271 | $44.16 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 91 | $21.21 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,194 | $2.40 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,542 | $1.10 |
| J2704 | Injection, propofol, 10 mg | 0% | 870 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 927 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 26 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 207 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 412 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 153 | $0.00 |
| 3074F | 0% | 70 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 262 | $0.00 |
| J3490 | Unclassified drugs | 0% | 69 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 17 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 14 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 2,617 | $0.00 |
| 3078F | 0% | 50 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 73 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUNSINGER, PATRICIA (CHEIF FINANCIAL OFFICER)